Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
The use of RNA-based treatments in the field of cancer immunotherapy
M Chehelgerdi, M Chehelgerdi - Molecular Cancer, 2023 - Springer
Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …
NY-ESO-1 based immunotherapy of cancer: current perspectives
R Thomas, G Al-Khadairi, J Roelands… - Frontiers in …, 2018 - frontiersin.org
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
Lung cancer: Biology and treatment options
H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response
PF Robbins, SH Kassim, TLN Tran, JS Crystal… - Clinical Cancer …, 2015 - AACR
Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients
with melanoma, the application of this approach to the treatment of other solid tumors has …
with melanoma, the application of this approach to the treatment of other solid tumors has …
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
PF Robbins, RA Morgan, SA Feldman… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an
effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 …
effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 …
Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE …
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for
patients with metastatic cancer. Most current strategies use genes that encode major …
patients with metastatic cancer. Most current strategies use genes that encode major …
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
M Sebastian, A Schröder, B Scheel, HS Hong… - Cancer immunology …, 2019 - Springer
CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung
cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen …
cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen …
Cancer/testis (CT) antigens: potential targets for immunotherapy
OL Caballero, YT Chen - Cancer science, 2009 - Wiley Online Library
Cancer/testis (CT) antigens are protein antigens with normal expression restricted to adult
testicular germ cells, and yet are aberrantly activated and expressed in a proportion of …
testicular germ cells, and yet are aberrantly activated and expressed in a proportion of …